Ainos, INC. (AIMDW) — SEC Filings

Overview

Ainos, INC. (AIMDW) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Dec 31, 2025: On December 30, 2025, Ainos, Inc. reported the unregistered sale of equity securities. The company, formerly known as Amarillo Biosciences Inc., is incorporated in Texas and its principal executive offices are located in San Diego, California.

Sentiment Summary

Across 46 filings, the sentiment breakdown is: 1 bullish, 3 bearish, 39 neutral, 3 mixed. The dominant filing sentiment for Ainos, INC. is neutral.

Filing Type Overview

Ainos, INC. (AIMDW) has filed 29 8-K, 5 10-Q, 2 DEF 14A, 4 SC 13D/A, 2 SC 13D, 1 DEFA14A, 1 S-1, 1 10-K, 1 10-Q/A with the SEC between Jan 2024 to Dec 2025.

Filings by Year

2025 · 2024

Recent Filings (46)

• Ainos, Inc. Reports Unregistered Equity Sales — 8-K · Dec 31, 2025 Risk: medium
  On December 30, 2025, Ainos, Inc. reported the unregistered sale of equity securities. The company, formerly known as Amarillo Biosciences Inc., is incorporated
• Ainos' Losses Mount Amid Revenue Growth, Cash Drains — 10-Q · Nov 13, 2025 Risk: high
  Ainos, Inc. (AIMDW) reported a net loss of $10,302,714 for the nine months ended September 30, 2025, a slight increase from the $10,209,149 net loss in the prio
• Ainos, Inc. Enters Material Definitive Agreement — 8-K · Oct 17, 2025 Risk: medium
  On October 15, 2025, Ainos, Inc. entered into a material definitive agreement. The company, formerly known as Amarillo Biosciences Inc., is incorporated in Texa
• Ainos Seeks Shareholder Nod for 950K Stock Awards, Auditor Ratification — DEF 14A · Oct 1, 2025 Risk: medium
  Ainos, Inc. (AIMDW) is holding its Annual Meeting of Stockholders on November 7, 2025, in Taiwan, with a record date of September 17, 2025. Key proposals includ
• Ainos, Inc. Files 8-K Report — 8-K · Sep 8, 2025 Risk: low
  On September 5, 2025, Ainos, Inc. filed an 8-K report detailing "Other Events" and "Financial Statements and Exhibits." The filing was made public on September
• Ainos, Inc. Files 8-K Report — 8-K · Aug 13, 2025 Risk: low
  On August 13, 2025, Ainos, Inc. filed an 8-K report. The filing indicates the company's fiscal year ends on December 31st. Ainos, Inc. is incorporated in Texas
• Ainos' Losses Widen to $7.37M Amid Cash Burn, Reverse Stock Split — 10-Q · Aug 13, 2025 Risk: high
  Ainos, Inc. (AIMDW) reported a net loss of $7,371,012 for the six months ended June 30, 2025, an increase from a net loss of $6,509,832 for the same period in 2
• Ainos, Inc. Files 8-K Report — 8-K · Aug 7, 2025 Risk: low
  On August 6, 2025, Ainos, Inc. filed an 8-K report detailing other events and financial statements. The company, formerly known as Amarillo Biosciences Inc., is
• Ainos, Inc. Appoints New Independent Auditor — 8-K · Jul 31, 2025 Risk: low
  On July 31, 2025, Ainos, Inc. filed an 8-K report to disclose changes in its certifying accountant. The company has appointed BDO USA, LLP as its new independen
• Ainos, Inc. Files 8-K Report — 8-K · Jul 16, 2025 Risk: low
  On July 16, 2025, Ainos, Inc. filed an 8-K report. The filing primarily concerns other events and financial statements/exhibits. Ainos, Inc. was formerly known
• Ainos, Inc. Files 8-K with Bylaw Amendments & Financials — 8-K · Jul 1, 2025 Risk: low
  Ainos, Inc. filed an 8-K on June 30, 2025, reporting amendments to its articles of incorporation or bylaws and financial statements. The company, formerly Amari
• Ainos, Inc. Files 8-K Report — 8-K · Jun 24, 2025 Risk: low
  On June 24, 2025, Ainos, Inc. filed an 8-K report. The filing primarily concerns other events and financial statements/exhibits, with no specific material event
• Ainos, Inc. Files 10-Q for Q1 2025 — 10-Q · May 14, 2025 Risk: low
  Ainos, Inc. filed its 10-Q for the period ending March 31, 2025. The company, formerly Amarillo Biosciences Inc., is in the pharmaceutical preparations industry
• Ainos, Inc. Files 8-K on Financials — 8-K · May 12, 2025 Risk: low
  Ainos, Inc. filed an 8-K on May 12, 2025, reporting on its results of operations and financial condition, as well as financial statements and exhibits. The comp
• Ainos, Inc. Signs Material Definitive Agreement — 8-K · Mar 14, 2025 Risk: medium
  On March 12, 2025, Ainos, Inc. entered into a material definitive agreement. The company, formerly known as Amarillo Biosciences Inc., is incorporated in Texas
• Ainos, Inc. Files 8-K for Material Agreement — 8-K · Mar 11, 2025 Risk: medium
  On March 10, 2025, Ainos, Inc. entered into a material definitive agreement. The filing also includes financial statements and exhibits related to this agreemen
• Ainos, Inc. Files 8-K on Financials — 8-K · Mar 7, 2025 Risk: medium
  On March 7, 2025, Ainos, Inc. filed an 8-K report detailing results of operations and financial condition. The filing includes financial statements and exhibits
• Ainos, Inc. Files 8-K Report — 8-K · Mar 5, 2025 Risk: low
  On March 5, 2025, Ainos, Inc. filed an 8-K report detailing other events and financial statements/exhibits. The company, formerly known as Amarillo Biosciences
• Ainos, Inc. Files 8-K Report — 8-K · Dec 4, 2024 Risk: low
  On November 27, 2024, Ainos, Inc. filed an 8-K report detailing a Regulation FD Disclosure and Other Events. The filing also includes financial statements and e
• Ainos, Inc. Files SC 13D/A Amendment — SC 13D/A · Nov 27, 2024 Risk: medium
  On November 27, 2024, Ainos, Inc. filed an amendment (No. 9) to its Schedule 13D. The filing indicates changes in beneficial ownership of the company's common s
• Ainos, Inc. Files Q3 2024 10-Q Report — 10-Q · Nov 6, 2024 Risk: medium
  Ainos, Inc. filed its 10-Q for the period ending September 30, 2024. The company, formerly known as Amarillo Biosciences Inc., is in the pharmaceutical preparat
• Ainos, Inc. Signs Material Definitive Agreement — 8-K · Oct 22, 2024 Risk: medium
  On October 16, 2024, Ainos, Inc. entered into a Material Definitive Agreement. The company, formerly known as Amarillo Biosciences Inc., is incorporated in Texa
• Ainos, Inc. Seeks Shareholder Vote Approval — 8-K · Oct 1, 2024 Risk: medium
  On September 27, 2024, Ainos, Inc. filed an 8-K report detailing the submission of matters to a vote of its security holders. The filing indicates that the comp
• Taiwan Carbon Nano Tech Files 13D for Ainos, Inc. — SC 13D · Aug 21, 2024 Risk: medium
  On August 21, 2024, Taiwan Carbon Nano Technology Corp filed a Schedule 13D for Ainos, Inc. The filing indicates a change in beneficial ownership. Chun-Hsien Ts
• Ainos, Inc. CEO Files SC 13D/A Amendment — SC 13D/A · Aug 20, 2024 Risk: medium
  On August 20, 2024, Ainos, Inc. filed an SC 13D/A amendment. Chun-Hsien Tsai, CEO of Ainos, Inc., is listed as the filer, with his address in New Taipei City, T
• Ainos, Inc. Files Definitive Additional Materials Proxy Statement — DEFA14A · Aug 16, 2024 Risk: low
  Ainos, Inc. filed a Definitive Additional Materials proxy statement on August 16, 2024. This filing relates to the company's proxy materials, indicating it is p
• Ainos, Inc. Files Definitive Proxy Statement — DEF 14A · Aug 15, 2024 Risk: low
  Ainos, Inc. filed its definitive proxy statement (DEF 14A) on August 15, 2024. The filing concerns the company's annual meeting and related matters. Ainos, Inc.
• Ainos, Inc. Files 8-K: Material Agreement, Officer Changes — 8-K · Aug 9, 2024 Risk: medium
  On August 5, 2024, Ainos, Inc. entered into a material definitive agreement related to the unregistered sale of equity securities. The filing also disclosed the
• Ainos, Inc. Files 8-K on Financials — 8-K · Aug 5, 2024 Risk: low
  On August 5, 2024, Ainos, Inc. filed an 8-K report. The filing primarily concerns the company's financial condition and results of operations, along with financ
• Ainos, Inc. Faces Delisting Concerns — 8-K · Jul 19, 2024 Risk: high
  Ainos, Inc. filed an 8-K on July 19, 2024, reporting a notice of delisting or failure to meet continued listing standards. The company's stock was previously tr
• Ainos, Inc. Files 8-K for Material Definitive Agreement — 8-K · Jul 12, 2024 Risk: medium
  On July 8, 2024, Ainos, Inc. entered into a Material Definitive Agreement. The filing also includes financial statements and exhibits related to this agreement.
• Ainos, Inc. Files 8-K with Corporate Updates — 8-K · Jun 20, 2024 Risk: low
  Ainos, Inc. filed an 8-K on June 20, 2024, reporting events as of June 14, 2024. The filing includes amendments to its articles of incorporation or bylaws, a Re
• Ainos, Inc. Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 13, 2024 Risk: low
  Ainos, Inc. (AIMDW) filed a Quarterly Report (10-Q) with the SEC on May 13, 2024. Ainos, Inc. filed a 10-Q report for the period ending March 31, 2024. The comp
• ASE Tech Files 13D for Ainos, Inc. — SC 13D · May 8, 2024 Risk: medium
  ASE Technology Holding Co., Ltd. has filed a Schedule 13D for Ainos, Inc. on May 8, 2024. The filing indicates a change in ownership or control, with ASE Techno
• Ainos, Inc. Secures $1.5M Funding via Convertible Notes — 8-K · May 6, 2024 Risk: medium
  On May 3, 2024, Ainos, Inc. entered into a Material Definitive Agreement, specifically a Securities Purchase Agreement, with an accredited investor. This agreem
• Ainos, Inc. Files S-1 Amendment for Public Offering — S-1 · Apr 8, 2024 Risk: low
  Ainos, Inc. (AIMDW) filed a IPO Registration (S-1) with the SEC on April 8, 2024. Ainos, Inc. filed an S-1 Amendment on April 8, 2024. The company is incorporat
• Ainos, Inc. Files 8-K: Board Changes and Compensation Updates — 8-K · Mar 19, 2024 Risk: medium
  Ainos, Inc. announced on March 15, 2024, a change in its board of directors and executive compensation arrangements. The filing details the departure of certain
• Ainos, Inc. Reports Board Changes and Officer Compensation — 8-K · Mar 15, 2024 Risk: low
  Ainos, Inc. announced on March 13, 2024, a change in its board of directors. Specifically, the company reported the departure of Director Jianjun Liu and the el
• Ainos, Inc. CEO Files Schedule 13D/A Amendment — SC 13D/A · Mar 11, 2024 Risk: low
  On March 7, 2024, Ainos, Inc. filed an amendment (No. 6) to its Schedule 13D. The filing indicates that Chun-Hsien Tsai, the CEO of Ainos, Inc., is the reportin
• Ainos, Inc. Files 2023 Annual Report on Form 10-K — 10-K · Mar 8, 2024 Risk: medium
  Ainos, Inc. (AIMDW) filed a Annual Report (10-K) with the SEC on March 8, 2024. Ainos, Inc. reported its 2023 fiscal year-end results on March 8, 2024. The comp
• Ainos, Inc. Files 10-Q/A Amendment for Period Ending September 30, 2023 — 10-Q/A · Feb 15, 2024 Risk: medium
  Ainos, Inc. (AIMDW) filed a Amended Quarterly Report (10-Q/A) with the SEC on February 15, 2024. Ainos, Inc. filed a 10-Q/A amendment on February 15, 2024, for
• Ainos to Present at MicroCap Rodeo Winter Wonderland Conference — 8-K · Feb 5, 2024
  Ainos, Inc. filed an 8-K on February 5, 2024, to disclose that it will be making a presentation at the MicroCap Rodeo Winter Wonderland Best Ideas Conference 20
• Ainos CEO Tsai Amends 13D Filing, Updates Ownership Stake — SC 13D/A · Jan 29, 2024
  Chun-Hsien Tsai, the CEO of Ainos, Inc., filed an Amendment No. 5 to his Schedule 13D on January 26, 2024, indicating a change in his beneficial ownership of Ai
• Ainos (AIMD) Enters Material Agreement, Incurs Financial Obligation — 8-K · Jan 25, 2024
  Ainos, Inc. (AIMD) filed an 8-K on January 25, 2024, reporting that on January 23, 2024, it entered into a material definitive agreement and incurred a direct f
• Ainos Enters Material Agreement for Stock & Warrants Issuance — 8-K · Jan 12, 2024
  Ainos, Inc. entered into a material definitive agreement on January 8, 2024, for the issuance of common stock and warrants. This filing indicates a potential ca
• Ainos Files Routine 8-K for 'Other Event' on Dec 29, 2023 — 8-K · Jan 2, 2024
  Ainos, Inc. filed an 8-K on January 2, 2024, reporting an 'Other Event' that occurred on December 29, 2023. This filing is a routine disclosure and does not con

Risk Profile

Risk Assessment: Of AIMDW's 41 recent filings, 3 were flagged as high-risk, 19 as medium-risk, and 19 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Financial Highlights

Key financial metrics from Ainos, INC.'s most recent 10-Q filing (Nov 13, 2025):

• Revenue: $113,037
• Net Income: -$10,302,714
• EPS: -$2.61
• Debt-to-Equity: N/A
• Cash Position: $1,128,217
• Operating Margin: N/A
• Total Assets: N/A
• Total Debt: N/A

Key Executives

• Chun-Hsien Tsai
• Board of Directors
• Jianjun Liu

Industry Context

Ainos operates in a highly competitive and rapidly evolving sector, likely within biotechnology or medical devices, given its focus on product sales and R&D. The industry is characterized by significant capital requirements, long development cycles, and stringent regulatory oversight. Success often hinges on innovation, effective commercialization strategies, and securing adequate funding to navigate these challenges.

Top Tags

sec-filing (8) · 8-K (6) · material-agreement (5) · filing (5) · corporate-governance (5) · pharmaceuticals (4) · disclosure (4) · Nasdaq Compliance (3) · corporate-filing (3) · financial-reporting (3)

Key Numbers

• Net Loss: $10,302,714 — for the nine months ended September 30, 2025, an increase from $10,209,149 in 2024
• Revenues: $113,037 — for the nine months ended September 30, 2025, up from $20,729 in 2024
• Cash and Cash Equivalents: $1,128,217 — as of September 30, 2025, down from $3,892,919 at December 31, 2024
• Total Operating Expenses: $9,786,141 — for the nine months ended September 30, 2025, up from $9,175,704 in 2024
• Proceeds from At-the-Market Offering: $1,852,895 — net of issuance costs, for the nine months ended September 30, 2025
• Reverse Stock Split Ratio: 1-for-5 — effectuated on June 30, 2025, to comply with Nasdaq listing rules
• Net Loss Per Common Share: $0.64 — for the three months ended September 30, 2025, improved from $1.64 in 2024
• Net Cash Used in Operating Activities: $3,759,679 — for the nine months ended September 30, 2025
• SEC File Number: 001-41461 — Identifies the company's filing history with the SEC.
• IRS Employer Identification No.: 75-1974352 — Company's tax identification number.
• Shares of common stock reserved for special awards: 950,000 — Potential dilution not under the 2023 Stock Incentive Plan
• Shares of Common Stock outstanding: 4,771,184 — Entitled to vote as of the September 17, 2025 Record Date
• Date of Annual Meeting: November 7, 2025 — Meeting to be held at 5:30 p.m. Taiwan Standard Time
• Record Date: September 17, 2025 — Date for determining stockholders entitled to vote
• Potential dilution from special stock awards: 19.9% — Calculated as 950,000 shares / 4,771,184 shares outstanding

Related Companies

AIMD · ANNS

Frequently Asked Questions